Cargando…

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

Detalles Bibliográficos
Autores principales:	Gustine, Joshua N., Szalat, Raphael E., Staron, Andrew, Joshi, Tracy, Mendelson, Lisa, Sloan, J. Mark, Sanchorawala, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230421/ https://www.ncbi.nlm.nih.gov/pubmed/36546447 http://dx.doi.org/10.3324/haematol.2022.282264

Ejemplares similares

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
por: Gustine, Joshua N., et al.
Publicado: (2023)

Waldenström macroglobulinemia presenting as nephrotic syndrome: Renal heavy and light chain amyloidosis
por: Kwakernaak, Arjan J., et al.
Publicado: (2022)

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
por: Staron, Andrew, et al.
Publicado: (2021)

Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022)

Cutaneous amyloidosis as the first presentation of Waldenstrom macroglobulinemia
por: Rafiei, Rana, et al.
Publicado: (2020)

A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
por: Lu, Rebecca, et al.
Publicado: (2022)

Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013)

Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Secondary light chain amyloidosis with Waldenström’s macroglobulinemia and intermodal marginal zone lymphoma: A case report
por: Zhao, Zhen-Yu, et al.
Publicado: (2022)

Concurrent Waldenstrom Macroglobulinemia and Mutant Transthyretin Cardiac Amyloidosis
por: Qian, Xiaoxiao, et al.
Publicado: (2022)

Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases
por: Vergneault, Hélène, et al.
Publicado: (2021)

Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom's Macroglobulinemia
por: Jacob, Aasems, et al.
Publicado: (2017)

Waldenström Macroglobulinemia: Unusual Presentation With Cast Nephropathy/Light Chain Tubulopathy
por: Ashraf, Muddasir, et al.
Publicado: (2019)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
por: Büyükkurt, Nurhilal, et al.
Publicado: (2023)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials
por: Castillo, Jorge J., et al.
Publicado: (2020)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
por: Bai, Xueyan, et al.
Publicado: (2015)

1130. Low Risk of Pneumocystis jiroveci Pneumonia in Patients With Waldenstrom’s Macroglobulinemia on Ibrutinib
por: Kusztos, Amanda E, et al.
Publicado: (2018)

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
por: Castillo, Jorge J., et al.
Publicado: (2022)

Waldenstrom's macroglobulinemia associated with eosinophilia
por: You, Eunkyoung, et al.
Publicado: (2013)

How to manage Waldenstrom's macroglobulinemia
por: Buske, C, et al.
Publicado: (2013)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2016)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2015)

Cutaneous macroglobulinosis with Waldenström macroglobulinemia
por: Hassab-El-Naby, Hussein M.M., et al.
Publicado: (2020)

Genomic landscape of Waldenström's macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2019)

Bone localization of Waldenstrom’s macroglobulinemia
por: Daste, Camille, et al.
Publicado: (2023)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

A case of systemic amyloidosis showing papular/nodular lesions due to Waldenström's macroglobulinemia
por: Toma, Yumeno, et al.
Publicado: (2023)

A prognostic index predicting survival in transformed Waldenström macroglobulinemia
por: Durot, Eric, et al.
Publicado: (2020)

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
por: Gustine, Joshua N., et al.
Publicado: (2021)

Severe Acidemia in a Patient With Waldenström Macroglobulinemia
por: Hindi, Judy, et al.
Publicado: (2020)

Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
por: Xu, XiaoWei, et al.
Publicado: (2013)

Waldenstrom's macroglobulinemia presenting with lytic bone lesions: a rare presentation
por: Pujani, Mukta, et al.
Publicado: (2013)

Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia
por: Brolly, Aurélie, et al.
Publicado: (2012)

Splenic re-irradiation for waldenstrőm’s macroglobulinemia
por: Wei, Zhou, et al.
Publicado: (2012)

Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia
por: Kratochvil, David, et al.
Publicado: (2012)

Clinical Features of Waldenstrom Macroglobulinemia in Korea
por: Bang, Soo-Mee, et al.
Publicado: (2004)

CNS Vasculitis Associated with Waldenström Macroglobulinemia
por: Riangwiwat, Tanawan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b9idlofgdd21prrcku2lqshr0b